Cargando…

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study

OBJECTIVE: To assess the efficacy, safety, and tolerability of cariprazine in the treatment of the depressed phase of bipolar I disorder in adults (NCT02670538). METHODS: In this phase 3 double‐blind placebo‐controlled study, adult patients with bipolar I disorder according to the Diagnostic and Sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Earley, Willie R., Burgess, Maria V., Khan, Barbara, Rekeda, Ludmyla, Suppes, Trisha, Tohen, Mauricio, Calabrese, Joseph R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318333/ https://www.ncbi.nlm.nih.gov/pubmed/31628698 http://dx.doi.org/10.1111/bdi.12852

Ejemplares similares

Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies
por: McIntyre, Roger S., et al.
Publicado: (2020)

Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies
por: Patel, Mehul, et al.
Publicado: (2020)

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial
por: Yatham, Lakshmi N., et al.
Publicado: (2020)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
por: Tohen, Mauricio
Publicado: (2021)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
por: Young, Allan H, et al.
Publicado: (2013)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
por: Findling, Robert L, et al.
Publicado: (2018)

Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy
por: Tarzian, Martin, et al.
Publicado: (2023)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study
por: Gonzalez, Robert, et al.
Publicado: (2018)

Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
por: Kato, Tadafumi, et al.
Publicado: (2020)

Cariprazine add-on for resistant bipolar depression: preliminary results from an italian real-world experience
por: Martiadis, V., et al.
Publicado: (2023)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
por: Werner, Felix-Martin, et al.
Publicado: (2015)

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014)

Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design
por: Tohen, Mauricio
Publicado: (2017)

Cariprazine pharmacokinetics
Publicado: (2022)

Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
por: Stahl, Stephen M., et al.
Publicado: (2020)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study
por: Wang, Gang, et al.
Publicado: (2016)

A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
por: Toniolo, Ricardo Alexandre, et al.
Publicado: (2017)

A pilot trial of quetiapine, lithium, or placebo added to divalproex sodium for hypomanic or manic episodes in ambulatory adults with bipolar I disorder
por: Cosgrove, Victoria E., et al.
Publicado: (2022)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia
por: Cosgrove, Victoria E, et al.
Publicado: (2013)

Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials
por: Suppes, Trisha, et al.
Publicado: (2017)

Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
por: Murasaki, Mitsukuni, et al.
Publicado: (2018)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial
por: Savitz, Jonathan B., et al.
Publicado: (2018)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_558bj6ipaotksstlc0f3hlho0p